Trial Profile
Short term effects of letrozole [Femara] on bone markers and vascular indices in postmenopausal women after completion of tamoxifen therapy for primary breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2010
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer; Osteoporosis
- Focus Biomarker; Pharmacodynamics
- 09 Dec 2005 New trial record.